Feature | Left Atrial Appendage (LAA) Occluders | November 07, 2016

Positive Data for Watchman LAA Occluder Real-world Post-FDA Approval Experience

Study finds high procedural success, low complication rates despite ilarge percentage of new operators

watchman LAA occluder, LAAO registry

November 7, 2016 – Results from the U.S. real-world, post-FDA approval experience of the Watchman device found high procedural success and low complication rates despite implantations by a large percentage of new operators. The Watchman device was approved by the U.S. Food and Drug Administration (FDA) in March 2015 for left atrial appendage occlusion (LAAC) to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AF). 

Findings from the Watchman US Post-Approval Experience were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The results of the study were also published simultaneously in the Journal of the American College of Cardiology (JACC).

“While LAAC avoids the anticoagulant-related lifetime risk of bleeding, implantation of the device can be associated with upfront complications,” said lead investigator Vivek Y. Reddy, MD. Dr. Reddy is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai. “Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as the therapy is introduced into general clinical practice.”

Despite the absence of a formal national prospective clinical registry, the researchers were able to collect procedural data on all LAAC procedures since FDA approval. The manufacturer required a clinical specialist be present at all cases, and procedure parameters and major complications were collected and reported using a standardized process and forms.

Watch the video “Post-FDA Approval Experience of LAA Occluders at ACC.16,” an interview with David Holmes, M.D., professor of medicine, Mayo Clinic College of Medicine and consultant, Department of Internal Medicine, Division of Cardiovascular Diseases,

In this multicenter, prospective registry, 3,822 consecutive patients underwent device implantation by 382 operating physicians in the U.S. The operators included both those who had previously performed LAAC procedures as part of clinical trials (29%), as well as “naive” operators (71%) - those physicians who had not previously performed any Watchman procedures prior to FDA approval. This latter physician group performed 50% of all procedures in the 3,822 patient cohort.

The procedure was successfully performed in 3,653 of 3,822 patients (95.6%) with an average duration of 50 minutes. The most prevalent complication reported was pericardial effusion requiring intervention in 39 patients (1.02%). Procedure-related stroke was 0.08% (n=3) and the mortality rate was 0.08% (n=3). There were nine (0.24%) instances of device embolization; two-thirds (n=6) of these required surgical removal, while the remaining third (n=3) were removed percutaneously. All but one of the device embolizations were identified either during the procedure (n=5) or while the patient was recovering in the hospital (n=3).

“The data shows that the U.S. clinical experience with LACC using the Watchman device has been favorable,” said Dr. Reddy. “Since the device was approved by the FDA, the technology has been used in increasing numbers of patients and procedural success rates remain high. In addition, despite a large percentage of previously inexperienced operators performing the implantation procedures, complication rates continue to improve compared to earlier clinical trials.”

The WATCHMAN US POST-APPROVAL STUDY trial was funded by Boston Scientific. Reddy has received research grant support from and has been a consultant for Boston Scientific, Coherex, SentreHeart and St Jude Medical.

Read the article, “Occluding the Left Atrial Appendage (LAA),” an update on LAA occlusion technology from mid-2016.

For more information: www.crf.org


Related Content

News | Left Atrial Appendage (LAA) Occluders

May 25, 2023 — Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and ...

Home May 25, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

May 22, 2023 — Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and ...

Home May 22, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

March 28, 2023 — The Society for Cardiovascular Angiography and Interventions (SCAI) and the Heart Rhythm Society (HRS) ...

Home March 28, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

February 27, 2023 — Conformal Medical, Inc. announced today the results from the CONFORMAL Early Feasibility Study (EFS) ...

Home February 27, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

December 22, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

Home December 22, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

September 12, 2022 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to ...

Home September 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

June 27, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home June 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

April 12, 2022 – Patients who had leakage to the left atrial appendage due to incomplete device sealing after left ...

Home April 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders
February 28, 2022 – Boston Scientific Corporation has announced positive results from a new analysis assessing real ...
Home February 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

Home November 08, 2021
Home
Subscribe Now